Conmed (NASDAQ: CNMD) reported Q3 EPS of $0.80, $0.04 better than the analyst estimate of $0.76. Revenue for the quarter came in at $248.8 million versus the consensus estimate of $255.53 million.

GUIDANCE:

Conmed sees FY2021 EPS of $3.18-$3.23, versus the consensus of $3.19.

For earnings history and earnings-related data on Conmed (CNMD) click here.